MAC3702 Assignment
2 (COMPLETE
ANSWERS) Semester 2
2025 - DUE 12
September 2025
[Document subtitle]
[School]
[Course title]
, MAC3702 Assignment 2 (COMPLETE ANSWERS) Semester 2 2025 - DUE 12 September 2025
Course
Application of Financial Management Techniques (MAC3702)
Institution
University Of South Africa (Unisa)
Book
Managerial Finance
MAC3702 Assignment 2 (COMPLETE ANSWERS) Semester 2 2025 - DUE 12 September 2025;
100% TRUSTED Complete, trusted solutions and explanations.
QUESTION 1 (72 marks) GlucoCare Limited is a healthcare technology and pharmaceutical
company based in Johannesburg, Gauteng. The company is dedicated to making diabetes
management more affordable and accessible to patients across South Africa. In early 2024,
GlucoCare identified that one of the biggest barriers for diabetic patients is the high cost of
continuous glucose monitoring (CGM) systems and insulin delivery devices. In response, the
company developed GlucoTrack-Lite, a compact, wearable glucose monitor that pairs with a
smartphone app and provides real-time blood sugar readings at a fraction of the cost of
traditional CGM devices. The device also incorporates a smart alert system to notify users —
and their doctors — of dangerous fluctuations, potentially preventing severe complications.
Remarkably, early testing showed that patients using GlucoTrack-Lite improved their average
glucose stability within 3–5 days of use — far quicker than the several weeks usually required
for behavioural and dosage adjustments to show measurable benefits. GlucoCare Limited’s
mission is to become the leading provider of affordable diabetes management solutions in
South Africa, believing that effective monitoring and timely intervention can significantly reduce
hospital admissions and long-term complications for diabetic patients. The breakthrough
attracted the attention of the National Department of Health, which awarded GlucoCare a grant
to roll out a national pilot project. During the pilot phase, the company distributed GlucoTrack-
Lite devices to public clinics, endocrinology practices, and select pharmacies nationwide,
receiving overwhelmingly positive feedback from patients and healthcare providers. The pilot
phase cost is R575 000. The following financial information was sourced from GlucoCare
Limited’s integrated annual report: The earnings before tax for the year ending 31 May 2025
were correctly calculated at R (2024: R). The industry norm for return on assets is 8%, the debt-
to-equity ratio norm is 1:1, and the total assets-to-total liabilities norm is 4 times. Extract from
the Statement of Financial Position at 31 May 2025: Notes R’000 Ordinary shares 1,2 575 000
2 (COMPLETE
ANSWERS) Semester 2
2025 - DUE 12
September 2025
[Document subtitle]
[School]
[Course title]
, MAC3702 Assignment 2 (COMPLETE ANSWERS) Semester 2 2025 - DUE 12 September 2025
Course
Application of Financial Management Techniques (MAC3702)
Institution
University Of South Africa (Unisa)
Book
Managerial Finance
MAC3702 Assignment 2 (COMPLETE ANSWERS) Semester 2 2025 - DUE 12 September 2025;
100% TRUSTED Complete, trusted solutions and explanations.
QUESTION 1 (72 marks) GlucoCare Limited is a healthcare technology and pharmaceutical
company based in Johannesburg, Gauteng. The company is dedicated to making diabetes
management more affordable and accessible to patients across South Africa. In early 2024,
GlucoCare identified that one of the biggest barriers for diabetic patients is the high cost of
continuous glucose monitoring (CGM) systems and insulin delivery devices. In response, the
company developed GlucoTrack-Lite, a compact, wearable glucose monitor that pairs with a
smartphone app and provides real-time blood sugar readings at a fraction of the cost of
traditional CGM devices. The device also incorporates a smart alert system to notify users —
and their doctors — of dangerous fluctuations, potentially preventing severe complications.
Remarkably, early testing showed that patients using GlucoTrack-Lite improved their average
glucose stability within 3–5 days of use — far quicker than the several weeks usually required
for behavioural and dosage adjustments to show measurable benefits. GlucoCare Limited’s
mission is to become the leading provider of affordable diabetes management solutions in
South Africa, believing that effective monitoring and timely intervention can significantly reduce
hospital admissions and long-term complications for diabetic patients. The breakthrough
attracted the attention of the National Department of Health, which awarded GlucoCare a grant
to roll out a national pilot project. During the pilot phase, the company distributed GlucoTrack-
Lite devices to public clinics, endocrinology practices, and select pharmacies nationwide,
receiving overwhelmingly positive feedback from patients and healthcare providers. The pilot
phase cost is R575 000. The following financial information was sourced from GlucoCare
Limited’s integrated annual report: The earnings before tax for the year ending 31 May 2025
were correctly calculated at R (2024: R). The industry norm for return on assets is 8%, the debt-
to-equity ratio norm is 1:1, and the total assets-to-total liabilities norm is 4 times. Extract from
the Statement of Financial Position at 31 May 2025: Notes R’000 Ordinary shares 1,2 575 000
